DNLI - Denali Therapeutics Inc.

19.7
-0.670   -3.401%

Share volume: 1,452,926
Last Updated: 03-05-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.04%

PREVIOUS CLOSE
CHG
CHG%
$20.37
-0.67
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
24%
Profitability 0%
Dept financing 27%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-6.19%
1 Month
-6.55%
3 Months
0.05%
6 Months
27.10%
1 Year
21.08%
2 Year
-4.00%
Key data
Stock price
$19.70
P/E Ratio 
0.00
DAY RANGE
$19.45 - $20.63
EPS 
-$2.97
52 WEEK RANGE
$10.57 - $23.77
52 WEEK CHANGE
$18.03
MARKET CAP 
2.421 B
YIELD 
N/A
SHARES OUTSTANDING 
158.591 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
07-31-2025
BETA 
2.16
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,460,206
AVERAGE 30 VOLUME 
$1,598,801
Company detail
CEO: Ryan J. Watts
Region: US
Website: denalitherapeutics.com
Employees: 430
IPO year: 2017
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Denali Therapeutics Inc. discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate product candidate. BIIB122/DNL151, a small molecule inhibitor, is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease.

Recent news